GLP-1 receptor agonists are short peptide chains that mimic the incretin hormone glucagon-like peptide-1 (GLP-1). These compounds bind to GLP-1 receptors in the hypothalamus and pancreas, triggering multiple metabolic effects: delayed gastric emptying (slowing food passage to the intestines), enhanced glucose-dependent insulin secretion, and reduced appetite signaling. Single agonists target GLP-1 receptors alone, while dual agonists add GIP (glucose-dependent insulinotropic polypeptide) receptor activation, and triple agonists further engage glucagon receptors, producing increasingly potent metabolic effects and greater weight loss in clinical trials.
Single, Dual & Triple
In published clinical trials
For weight management
As of 2024–2025
Across published trial data, the ranking is not a close call. Retatrutide's triple-agonist mechanism (GLP-1 + GIP + glucagon) produces the largest weight reductions ever observed in the class, ~28.7% mean body-weight loss at 68 weeks in the 12 mg cohort of TRIUMPH-4. Tirzepatide (20–22%) is second. Semaglutide (17–21%) is third.
The catch: Retatrutide is not yet FDA-approved. NDA submission is expected late 2026 / early 2027, with approval potentially 2027–2028. Until then, Tirzepatide is the most effective approved option, and Semaglutide remains the most established safety record. The full comparison is below.
Comprehensive overview of GLP-1, dual, and triple agonists with latest clinical trial data. All FDA status information as of April 2026. Ordered by observed efficacy.
| Compound | Brand Names | Mechanism | FDA Status | Avg Weight Loss | Administration | Key Side Effects | Unique Advantage |
|---|---|---|---|---|---|---|---|
| Retatrutide #1 EFFICACY | Investigational (no brand yet) | Triple GLP-1/GIP/glucagon agonist | Phase 3 Trials | ~28.7% (12 mg, TRIUMPH-4) | Weekly subcutaneous injection (in trials) | Nausea, constipation, vomiting, diarrhea, dysesthesia (~20% at highest dose) | Highest weight loss ever observed in the class; glucagon activation adds energy expenditure and lipolysis on top of appetite suppression. Not yet approved. |
| Tirzepatide | Mounjaro, Zepbound | Dual GIP/GLP-1 agonist | FDA Approved | 20–22.5% (15 mg) | Weekly subcutaneous injection | Nausea, constipation, vomiting, diarrhea, abdominal pain | Currently the most effective FDA-approved option. Beat semaglutide head-to-head in SURMOUNT-5. |
| Semaglutide | Ozempic, Wegovy, Rybelsus | GLP-1 agonist | FDA Approved | 17% (2.4 mg) to 21% (7.2 mg) | Weekly subcutaneous or daily oral | Nausea, constipation, vomiting, diarrhea, abdominal pain | Most established safety record, longest real-world data, and the only oral option (Rybelsus). |
Detailed research pages for each GLP-1 class, including mechanism studies, clinical trial summaries, and safety profiles.
The most effective weight-loss compound ever tested in the GLP-1 class. Triple receptor agonist (GLP-1 + GIP + glucagon). The added glucagon activation layers energy expenditure and fat oxidation on top of appetite suppression, producing ~28.7% mean body-weight loss at 68 weeks in the TRIUMPH-4 12 mg cohort. Not yet approved; NDA expected late 2026 / early 2027.
Learn more →The most effective approved option available right now. Dual GIP/GLP-1 agonist. Produces 20–22.5% weight loss at the 15 mg dose and beat semaglutide head-to-head in SURMOUNT-5. Until retatrutide reaches market, this is the top-of-class choice clinicians can actually prescribe.
Learn more →The original, still relevant for its safety record and accessibility. Pure GLP-1 agonist. Produces 17–21% weight loss depending on dose. Longest real-world use of the three, the only oral option (Rybelsus), and typically the most affordable, but outperformed on efficacy by both tirzepatide and retatrutide.
Learn more →GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient intake, particularly glucose. GLP-1 receptor agonists are synthetic peptides that bind to and activate GLP-1 receptors distributed throughout the body, including in pancreatic beta cells, the hypothalamus, and gastrointestinal smooth muscle. When GLP-1 receptors are activated, they trigger a cascade of signaling pathways: beta cells increase glucose-dependent insulin secretion, the hypothalamus reduces appetite-promoting signals (decreasing orexigenic peptides like NPY and AgRP while increasing pro-opiomelanocortin neurons), and gastric smooth muscle relaxes, delaying gastric emptying. This combination of effects-enhanced insulin secretion, appetite suppression, and slower digestion-produces both glycemic control and weight loss.
Dual agonists, such as tirzepatide, add activation of the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is a second incretin hormone that enhances insulin secretion and has been shown to regulate energy expenditure and body weight through additional hypothalamic pathways. By targeting both GLP-1 and GIP receptors simultaneously, dual agonists produce synergistic effects: greater insulin secretion, enhanced appetite suppression, and improved metabolic efficiency. Clinical trials demonstrate that dual agonists achieve superior weight loss compared to single GLP-1 agonists alone.
Triple agonists, such as investigational retatrutide, extend this approach by adding glucagon receptor activation. Glucagon normally increases hepatic glucose output and energy expenditure; when activated pharmacologically alongside GLP-1 and GIP signaling, it promotes lipolysis (fat breakdown) and increases resting energy expenditure. Early-phase clinical trials suggest triple agonists produce the most substantial weight loss observed to date, though the addition of glucagon signaling also increases reported adverse events, particularly gastrointestinal disturbances and dysesthesia (abnormal sensations). Understanding the mechanisms of these compounds is essential for evaluating their therapeutic potential and side effect profiles.
All comparison data on this page is drawn from peer-reviewed clinical trials, FDA labeling, and manufacturer-reported Phase 3 results. Each reference below links to a PubMed or ClinicalTrials.gov search for the source publication.
For educational and research purposes only. Not medical advice. Consult a licensed healthcare provider.
This content is provided for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. GLP-1 receptor agonists and related compounds are prescription medications subject to regulatory oversight and significant individual variability in response and tolerability. Before considering any GLP-1 receptor agonist or related therapeutic, consult with a licensed healthcare provider, endocrinologist, or obesity medicine specialist who can evaluate your individual health status, contraindications, and suitability for treatment. This site does not sell, distribute, or facilitate the acquisition of any peptides or pharmaceuticals.